NCT05893472招募中1 期
The Second Affiliated Hospital of Kunming Medical University
ZePing Zhou1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2023年4月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Overall response rate (ORR)
研究概览
简要总结
The purpose of this study is to investigate the efficacy and safety of the combination of venetoclax and HAA regimen in young, newly diagnosed acute myeloid leukemia patients under the age of 60.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The eligible subjects for enrollment in this study must meet all of the following criteria:
- •Patients with acute myeloid leukemia (excluding APL) who meet the diagnostic criteria of the World Health Organization (WHO) 2016 classification.
- •Patients with AML and multilineage dysplasia (MDS) and/or myeloproliferative neoplasms (MPN) who meet the WHO criteria without prior history of MDS or MPN.
- •Patients with AML who are not classified separately according to the WHO classification, except for those with acute megakaryoblastic leukemia with bone marrow fibrosis or myeloid sarcoma.
- •Age greater than 16 years and less than 60 years, regardless of gender.
- •Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0-
- •Requirements for laboratory parameters (within 7 days prior to treatment initiation) include: aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤3 times the upper limit of normal (ULN); serum bilirubin ≤2×ULN; serum cardiac enzyme <2.0×ULN; serum creatinine ≤2.0×ULN; and echocardiogram (ECHO)-determined ejection fraction within the normal range.
- •A signed informed consent form is required before any study-specific procedures are performed. Patients 18 years and older may sign the informed consent form themselves or have it signed by their next of kin. Patients under 18 years of age must have the informed consent form signed by their legal guardian. In consideration of the patient's medical condition, if it is not in the patient's best interest to sign the form, the legal guardian or patient's next of kin may sign the form on the patient's behalf.
排除标准
- •Subjects meeting any of the following criteria will be excluded from this study:
- •Previously treated patients (including those who have undergone induction chemotherapy regardless of treatment response).
- •Secondary leukemia (including therapy-related AML subtype according to the World Health Organization (WHO) classification and those with a history of MDS and/or MPD).
- •Concomitant hematologic diseases (such as hemophilia or myelofibrosis) deemed unsuitable for inclusion by the investigator; individuals with prior abnormal blood counts are allowed to participate if they have been previously excluded from MDS and MPD.
- •Other malignant tumors requiring treatment.
- •Pregnant or lactating women. Female participants of childbearing potential must have a negative pregnancy test within 7 days prior to the start of the trial. Male or female participants must take contraceptive measures during the trial and for 3 years after completion of treatment.
- •Significant abnormalities in liver or kidney function beyond the inclusion criteria.
- •Active heart disease, defined as one or more of the following:
- •History of uncontrolled or symptomatic angina pectoris;
- •Myocardial infarction within 6 months prior to enrollment;
- •History of arrhythmia requiring medication or with severe clinical symptoms;
- •Uncontrolled or symptomatic congestive heart failure (> NYHA class 2);
- •Ejection fraction below the lower limit of the normal range.
- •Severe infectious diseases (e.g., unhealed tuberculosis or pulmonary aspergillosis).
- •Participants deemed unsuitable for inclusion by the investigator.
结局指标
主要结局
Overall response rate (ORR)
时间窗: up to 12 months
which evaluates the efficacy of patient induction therapy, including complete remission (CR), complete remission with incomplete blood count recovery (CRi), and morphologic leukemia-free state (MLFS)
次要结局
- overall survival (OS)(up to 12 months)
- relapse-free survival (RFS)(up to 12 months)
- Minimal residual disease (MRD)(up to 12 months)
- 30-day mortality rate(Within 30 days after starting the medication)
- adverse drug reactions(up to 12 months)
研究者
ZePing Zhou
Dr.
The Second Affiliated Hospital of Kunming Medical University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAMLSecondary Acute Myeloid LeukemiaNCT05513131The First Affiliated Hospital with Nanjing Medical University30
终止
1 期
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)Acute Myeloid LeukemiaNCT06158100Antonio M Jimenez Jimenez2
已完成
2 期
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic LeukemiaT-cell Prolymphocytic Leukemia (T-PLL)CancerLeukemiaNCT03873493AbbVie14
已完成
2 期
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT06068621Chinese PLA General Hospital200
终止
1 期
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic SyndromeTherapy-Related Myelodysplastic SyndromeNCT04550442M.D. Anderson Cancer Center34